Previous close | 96.22 |
Open | 95.28 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 93.32 - 96.32 |
52-week range | 93.32 - 96.32 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 0.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary Results/Development of SalesSHOP APOTHEKE EUROPE: STRONG ORGANIC GROWTH CONTINUES. 11.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.SHOP APOTHEKE EUROPE: STRONG ORGANIC GROWTH CONTINUES. Q4 total sales up by 14% year over year to EUR 328 million. Full year 2022 double-digit sales growth of 14% achieved; record EUR 1.2 billion total sales. Non-Rx sales growth 17% for the full year; 2022
EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): SustainabilityAt the VISION 2045 Summit alongside the COP 27: CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh. 10.11.2022 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement.At the VISION 2045 Summit alongside the COP 27:CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh.Sevenum, November 10, 2022. From 07 to 09 November 2022,
EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Interim Report/9 Month figuresSHOP APOTHEKE EUROPE: SOLID AND SUCCESSFUL QUARTER, FULLY IN LINE WITH GUIDANCE. BETTER MARGINS AND CONTINUED MARKET SHARE GAINS. 31.10.2022 / 06:29 CET/CESTThe issuer is solely responsible for the content of this announcement.SHOP APOTHEKE EUROPE: SOLID AND SUCCESSFUL QUARTER, FULLY IN LINE WITH GUIDANCE. BETTER MARGINS AND CONTINUED MARKET SHARE GAINS. Group sales up 20% to EUR 285 million in Q3 (9M up 14% to EUR